RxDoctor Payments Data

Michael Gardner, MD

Urology · Tualatin, ORNPI 1215993845

Payments from drug & device makers

$1,408in general payments, 2019–2025

Across 74 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$706
  • Abiomed$138
  • Antares Pharma, Inc.$123
  • 180 Medical, Inc.$48
  • AbbVie$46
  • Clarus Therapeutics Inc.$42
  • plus $306 from 13 others

What the payments were for

  • Food & beverage$1,30793%
  • Education$1017%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,408 in reported general payments places this provider in the 45th percentile of 153 urology providers in Oregon.

See all urology providers in Oregon

Medicare billing

Part B allowed, 2024
$232,154
Medicare patients
675
Services billed
4,857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron223$181,895
GemtesaVibegron82$74,834
Tamsulosin Hcl1,438$25,509
XyostedTestosterone Enanthate31$20,222
Methenamine Hippurate146$12,079
ElmironPentosan Polysulfate Sodium11$10,730
Finasteride784$9,955
Testosterone57$9,015
Potassium Citrate ErPotassium Citrate67$6,362
Testosterone Cypionate74$4,058
Dutasteride102$2,860
Solifenacin Succinate91$2,378
Oxybutynin Chloride117$2,167
RenacidinCitric Ac/Gluconolact/Mag Carb11$2,048
Alfuzosin Hcl ErAlfuzosin Hcl86$1,735

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$706$181,895223 claims
Antares Pharma, Inc.Xyosted$123$20,22231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 153 urology providers in Oregon.

Other urology in Tualatin

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →